金冠股份 reported revenue of ¥0.38B for the period ended 2026-06-30, -21.9% year on year. Net income was ¥-0.07B, a -19.5% net margin on a 11.8% gross margin. The largest revenue line is 输配电及控制设备 at 69% of the total. Free cash flow for the period was ¥-0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.38B | -21.9% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥-0.07B | — |
| Net income | ¥-0.07B | — |
| Gross margin | 11.8% | Net margin -19.5% |
| Revenue Q/Q | +65.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 输配电及控制设备 | ¥0.26B | 68.7% |
| 仪器仪表制造 | ¥0.04B | 11.7% |
| 充电桩制造及场站运营 | ¥0.04B | 11.0% |
| 其他 | ¥0.03B | 8.4% |
| 储能业务 | ¥0.00B | 0.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.33B | 88.2% |
| R&D | ¥0.03B | 6.8% |
| SG&A | ¥0.10B | 25.9% |
| Tax & other | ¥0.00B | 0.2% |
| Item | Amount |
|---|---|
| Total assets | ¥2.73B |
| Total liabilities | ¥0.86B |
| Shareholders' equity | ¥1.88B |
| Equity / assets | 68.6% |
| Operating cash flow | ¥-0.07B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.07B |
| Cash conversion (OCF / net income) | 122% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
雪榕生物 ・ 中亚股份 ・ 恒实科技 ・ 友讯达 ・ 三德科技 ・ 久之洋 ・ 海波重科 ・ 新迅达 ・ 新光药业 ・ 科大国创 ・ 爱司凯 ・ 世名科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies